Home: PCU
1|2003: Gerald W Chodak, MD: Select publications
Select publications
Dreicer R. Controversies in the systemic management of
patients with evidence of biochemical failure following radical
prostatectomy. Cancer Treat Rev 2002;28(4):189-94. Abstract
Granfors T et al. Combined orchiectomy and external radiotherapy
versus radiotherapy alone for nonmetastatic prostate cancer with
or without pelvic lymph node involvement: A prospective randomized
study. J Urol 1998;159(6):2030-4. Abstract
Grossfeld GD et al. Androgen deprivation therapy for patients
with clinically localized (stages T1 to T3) prostate cancer and
for patients with biochemical recurrence after radical prostatectomy.
Urology 2001;58(2 Suppl 1):56-64. Abstract
Iversen P et al. A randomised comparison of bicalutamide
('Casodex') 150 mg versus placebo as immediate therapy either alone
or as adjuvant to standard care for early non-metastatic prostate
cancer. First report from the Scandinavian Prostatic Cancer
Group Study No. 6. Eur Urol 2002;42(3):204. Abstract
Iversen P et al. Bicalutamide monotherapy compared with
castration in patients with nonmetastatic locally advanced prostate
cancer: 6.3 years of follow-up. J Urol 2000;164(5):1579-82.
Abstract
Iversen P et al. Nonsteroidal antiandrogens: A therapeutic
option for patients with advanced prostate cancer who wish to retain
sexual interest and function. BJU Int 2001;87(1):47-56.
No abstract available.
Klotz L. Combined androgen blockade in prostate cancer:
Meta-analyses and associated issues. BJU Int 2001;87(9):806-13.
No abstract available.
Maximum androgen blockade in advanced prostate cancer:
An overview of the randomised trials. Prostate Cancer Trialists'
Collaborative Group. Lancet 2000;355(9214):1491-8. Abstract
Mcleod DG. Emerging role of adjuvant hormonal therapy.
Urology 2002;60(3 Suppl 1):13-20;discussion 21. Abstract
Meng MV, Carroll PR. Is it necessary to do staging pelvic
lymph node dissection for T1c prostate cancer? Curr Urol
Rep 2001;2(3):237-41. Abstract
Messing EM et al. Immediate hormonal therapy compared
with observation after radical prostatectomy and pelvic lymphadenectomy
in men with node-positive prostate cancer. N Engl J Med
1999;341(24):1781-8. Abstract
Naito S. Androgen deprivation in combination with radical
prostatectomy for localized prostate cancer. Int J Urol
2001;8(7):S19-21. Abstract
Patterson SG et al. Controversies surrounding androgen
deprivation for prostate cancer. Cancer Control 2002;9(4):315-25.
Full-text
Roach M 3rd et al. Predicting the risk of lymph node involvement
using the pre-treatment prostate specific antigen and Gleason score
in men with clinically localized prostate cancer. Int J
Radiat Oncol Biol Phys 1994;28(1):33-7. Abstract
Wirth M. Delaying/reducing the risk of clinical tumour
progression after primary curative procedures. Eur Urol
2001;40 Suppl 2:17-23. Abstract
Wolf JS Jr et al. Selection of patients for laparoscopic
pelvic lymphadenectomy prior to radical prostatectomy: A decision
analysis. Urology 1993;42(6):680-8. Abstract
Wolf JS Jr et al. The use and accuracy of cross-sectional
imaging and fine needle aspiration cytology for detection of pelvic
lymph node metastases before radical prostatectomy. J Urol
1995;153(3 Pt 2):993-9. Abstract
Zincke H et al. Role of early adjuvant hormonal therapy
after radical prostatectomy for prostate cancer. J Urol
2001;166(6):2208-15. Abstract
|
